Treating Autoimmune Conditions and Pain with Low Dose Naltrexone (LDN)
In treating autoimmune conditions, doctors normally say patients notice something around the four-month mark, and I was just wondering if that correlated with pain. That's a very good question, so we need to have cohort studies like autoimmune studies, you know, you know what our target is? Can we measure anything related to that target? What's the dose range that we see for that target? What are the symptoms that are altered for that target? So each one is a different cohort. So we have, you know, opioid, you know, a dependence that's a target. Chronic pain that's a target. If we want to have specific diagnoses in chronic pain, chronic back pain, fibromyalgia, and diabetic neuropathy, we can have all of these as different silos that need to be investigated with large populations. Right now, we have very small studies that are really difficult to reach, you know, validity in terms of saying this is the way we should be going.